Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol.14 , Issue 3 (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Integrative Approaches: Indian Medicinal Plants in the Management of Rare Diseases.

Chandrasekar R[1] , T Susmitha[2], Kanniyakumari M[3], Renga Sundari[4], Senthamil Veni S[5], Nimeshika Devi S.V.L[6], Divya Jayachandran[7], E.Sathya Priya[8], Saravanasingh Karan Chand Mohan Singh[9*], L.Sridevi[10], Ramamurthy Murugan[11]

[1]Medical officer, National Institute of Siddha, Ministry of AYUSH, Government of India, Chennai, India.

[2]Resident medical officer, National Institute of Siddha, Ministry of AYUSH, Government of India, Chennai, India.

[3]Associate Professor, Department of Udal Thathuvam, National Institute of Siddha, Ministry of AYUSH, Government of India, Chennai, India.

[4]Professor, Department of Nanju Maruthuvam, National Institute of Siddha, Ministry of AYUSH, Government of India, Chennai, India.

[5]Medical officer, National Institute of Siddha, Ministry of AYUSH, Government of India, Chennai, India.

[6]Assistant Professor (Sirappu Maruthuvam), Department of Siddhar Yoga Maruthuvam, National Institute of Siddha, Ministry of AYUSH, Government of India, Chennai, India

[7]Medical officer, National Institute of Siddha, Ministry of AYUSH, Government of India, Chennai, India.

[8]Medical officer, National Institute of Siddha, Ministry of AYUSH, Government of India, Chennai, India.

[9]Assistant Professor, Department of Maruthuvam, National Institute of Siddha, Ministry of AYUSH, Government of India, Chennai, India.

[10]Research Associate (Siddha), Siddha Clinical Research Unit, Central Council for Research in Siddha, New Delhi, India.

[11]Associate Professor, Department of Noi Naadal, National Institute of Siddha, Ministry of AYUSH, Government of India, Chennai, India.

Corresponding author:

Saravanasingh Karan Chand Mohan Singh,

MD (Siddha), PhD, Department of Maruthuvam, National Institute of Siddha, Chennai-47, India

Email: k.saravanasingh@gmail.com

.Cite this paper as Chandrasekar R , T Susmitha, Kanniyakumari M, Renga Sundari, Senthamil Veni S, Nimeshika Devi S.V.L, Divya Jayachandran, E.Sathya Priya, Saravanasingh Karan Chand Mohan Singh, L.Sridevi, Ramamurthy Murugan (2025) Integrative Approaches: Indian Medicinal Plants in the Management of Rare Diseases. Journal of Neonatal Surgery, 14, (3) 388-394

ABSTRACT

This comprehensive review synthesizes current evidence on the therapeutic potential of Indian medicinal plants in managing rare diseases, with particular focus on genetic disorders, autoimmune conditions, and rare cancers. The article examines the pharmacological properties, molecular mechanisms, clinical applications, and integrative approaches that combine traditional Ayurvedic wisdom with modern biomedical science. Through systematic analysis of 50 highly relevant studies from the literature, we explore how Ayurvedic principles such as Dosha balance, Prakriti-based personalization, and Rasayana therapy offer promising complementary strategies for conditions where conventional treatments often fall short. The review highlights the emergence of Ayurgenomics as a transformative paradigm for personalized medicine while addressing critical challenges in standardization, safety validation, and clinical translation.

INTRODUCTION

Rare diseases, encompassing genetic disorders, autoimmune conditions, and rare cancers, represent a significant global health burden affecting millions worldwide(1). Conventional therapeutic approaches often provide limited efficacy and are associated with substantial adverse effects, creating an urgent need for alternative and complementary treatment strategies(2). Indian medicinal plants, rooted in millennia-old Ayurvedic traditions, have emerged as promising candidates for addressing these complex conditions through their multifaceted pharmacological properties(3).

The integration of Ayurvedic principles with modern biomedical science has evolved significantly over the past two decades, progressing from early clinical trials to sophisticated integrative frameworks that combine traditional knowledge with

genomics, immunology, and nanotechnology(4). This evolution reflects a paradigm shift toward holistic, personalized approaches that acknowledge the complex interplay between genetic predisposition, immune dysregulation, and environmental factors in rare disease pathogenesis(5)..

Therapeutic Potential in Genetic Disorders

Neuromuscular and Muscular Dystrophies

Recent case reports demonstrate significant symptomatic and biochemical improvements in rare genetic disorders such as Limb-Girdle Muscular Dystrophy (LGMD) following Ayurvedic interventions(6). Wasedar et al. (2025) documented substantial recovery in an LGMD patient through a combination of oral medications and Panchakarma therapies, with improvements persisting over long-term follow-up(7). The Ayurvedic conceptualization of genetic defects as "Beeja Dushti" (seed defects) provides a unique framework for understanding hereditary conditions through the lens of Vata imbalance and tissue-specific pathology(8).

Mugali and DG (2024) reported similar success in managing LGMD symptoms using Ayurvedic approaches that target "Mamsagata Vata" (Vata affecting muscle tissue), highlighting the potential of traditional diagnostic frameworks in guiding therapeutic strategies(9). These findings are supported by broader reviews indicating that medicinal plants can improve muscle function in muscular dystrophies through multi-targeted effects on regeneration and oxidative stress reduction(10).

Hereditary Blood Disorders

Ayurvedic approaches to hereditary conditions extend to blood disorders such as Sickle Cell Disease, which is correlated with "Sannipatika Pandu" in traditional classifications(11). This conceptual mapping demonstrates how Ayurvedic frameworks can accommodate genetic conditions within existing diagnostic paradigms, potentially guiding therapeutic interventions that address both symptomatic manifestations and underlying constitutional imbalances(12).

Immunomodulatory Properties in Autoimmune Diseases

Mechanistic Insights

Approximately 25 studies have elucidated the molecular pathways through which Indian medicinal plants exert immunomodulatory and anti-inflammatory effects(13). Key herbs including Ashwagandha (*Withania somnifera*), Guduchi (*Tinospora cordifolia*), Haridra (*Curcuma longa*), and Amalaki (*Emblica officinalis*) demonstrate significant potential in modulating inflammatory biomarkers such as TNF-α, interleukins, and other mediators of autoimmune pathology(14).

The immunomodulatory properties of these plants align with Ayurvedic concepts of Agni (digestive/metabolic fire) and Ama (toxins), providing a traditional framework for understanding immune dysregulation(15). Bhat et al. (2013) systematically validated the immunomodulatory properties of 20 Indian medicinal plants, confirming their potential as safer alternatives to conventional immunosuppressants(16).

Clinical Applications in Rheumatological Conditions

Randomized controlled trials have demonstrated the efficacy of Ayurvedic formulations in autoimmune conditions such as rheumatoid arthritis (RA). Chopra et al. (2000) conducted a double-blind trial of the RA-1 formulation, reporting symptomatic improvement and a favorable safety profile with minimal adverse effects(17). Subsequent systematic reviews have consolidated evidence supporting Ayurvedic management of various autoimmune disorders, though they consistently note the need for larger, more rigorous trials(18).

P and Giri (2022) systematically reviewed 10 clinical studies on Ayurvedic management of autoimmune disorders, finding consistent evidence of efficacy particularly in rheumatoid arthritis, while highlighting limitations in dosage standardization and safety profiling(19). These findings are complemented by reviews of specific therapeutic approaches, such as Sharma's (2025) examination of Shodhana (purification) and Shamana (palliative) therapies in autoimmune conditions(20).

Anticancer Potential in Rare Cancers

Traditional Frameworks and Modern Integration

Ayurvedic oncology, conceptualized through the framework of "Arbuda" (tumors), offers holistic approaches to cancer management that complement conventional treatments(21). Sundaramourthy et al. (2024) proposed Ayurvedic detoxification and anti-toxic therapies for cancer management, focusing on Dosha imbalance and toxin removal mechanisms(22). This integrative perspective addresses not only tumor growth but also systemic factors contributing to cancer pathogenesis and progression.

Singh et al. (2025) cataloged classical Ayurvedic formulations for cancer management, highlighting their multi-factorial targeting of pathogenic mechanisms(23). These traditional approaches are increasingly being integrated with modern oncology through concepts such as integrative oncology, which seeks to combine the strengths of both systems while mitigating treatment side effects and improving quality of life(24).

Specific Anticancer Mechanisms

Preclinical studies have identified specific anticancer mechanisms of Ayurvedic herbs and formulations. Sun et al. (2013) demonstrated that *Clerodendrum viscosum* root extract selectively induces apoptosis in cervical cancer cells through a glycoprotein-mediated mechanism(25). Chatterjee et al. (2024) reviewed the application of Ayurvedic Bhasma (herbo-mineral preparations) in cancer treatment, highlighting their nanoparticle properties and potential for enhanced bioavailability and targeted delivery(26).

K et al. (2024) comprehensively reviewed the role of herbal medicines and Ayurveda in cancer treatment, emphasizing their potential to enhance immune response and reduce chemotherapy side effects(27). These mechanisms include tumor inhibition, immune system modulation, and protection against treatment-induced toxicity, suggesting valuable adjunctive

roles in comprehensive cancer care.

Emerging Nanotechnology Applications

Lopus (2022) explored the potential of nano-Ayurvedic medicine in cancer treatment, demonstrating how nanoparticle formulations can enhance drug delivery, improve target specificity, and potentially reduce toxicity(28). This emerging field represents a promising intersection of traditional herbal knowledge with advanced pharmaceutical technology, addressing longstanding challenges in bioavailability and standardization.

Ayurgenomics: Bridging Tradition and Modern Science

Conceptual Foundations

Ayurgenomics represents a transformative paradigm that integrates Ayurvedic constitutional types (Prakriti) with genomic and epigenetic data to enable personalized approaches to rare disease management(29). Bhandari et al. (2025) developed a holistic Ayurvedic management framework for genetic disorders that correlates classical genetic concepts with modern genomics(30). This integration facilitates understanding of disease heterogeneity and supports precision therapeutics tailored to individual constitutional profiles.

Mukerji and Asher (2011) established foundational principles of Ayurgenomics, demonstrating how Prakriti correlates with gene expression patterns and adaptive responses(31). Subsequent research has expanded these concepts, with Juyal et al. (2012) identifying distinct genetic markers in rheumatoid arthritis subgroups based on Prakriti classification(32).

Phenotypic Mapping and Diagnostic Integration

Innovative computational frameworks have emerged to bridge Ayurvedic and modern biomedical ontologies. Jangir et al. (2025) developed a systems perspective on rare diseases that integrates Human Phenotype Ontology with the Anukta (unclassified) framework of Ayurveda(33). Similarly, Joshi et al. (2024) created AyurPhenoClusters that define common molecular roots for rare diseases and uncover ciliary dysfunctions in syndromic conditions(34).

These approaches demonstrate how traditional phenotypic classifications can be mapped to modern genomic data, facilitating novel diagnostic categories and personalized treatment strategies that transcend organ-centric views of disease(35).

Epigenetic Dimensions

Recent research has expanded Ayurgenomics to include epigenetic dimensions. J and R (2025) explored the foundations of Ayurveda and epigenetics for preventive and precision healthcare, demonstrating how lifestyle and behavioral factors can modulate gene expression in alignment with Ayurvedic principles(36). Keerthi and Udainiya (2025) further examined Ayurvedic perspectives on epigenetics with respect to Prakriti influence, highlighting the potential for personalized interventions based on constitutional predispositions(37).

Reverse Pharmacology and Drug Discovery

Traditional Knowledge-Guided Discovery

The reverse pharmacology approach leverages traditional Ayurvedic knowledge to guide modern drug discovery processes(38). Sidhic et al. (2024) detailed how Ayurveda-inspired reverse pharmacology accelerates drug discovery by focusing on clinical evidence and molecular mechanisms validated through traditional use(39). This methodology represents a paradigm shift from conventional single-target drug development to multi-target approaches that better reflect the complex pathophysiology of rare diseases.

Balachandran and Govindarajan (2007) earlier established the foundations of Ayurvedic drug discovery, highlighting how traditional knowledge can offer unique therapeutic leads for complex conditions(40). This approach has gained increasing recognition as a valuable strategy for identifying novel compounds and formulations with potential applications in rare disease management.

Clinical Validation and Evidence Base

Strengths and Limitations

The clinical evidence supporting Ayurvedic interventions in rare diseases encompasses diverse study designs including case reports, observational studies, randomized controlled trials, and systematic reviews(41). Case reports such as those by Wasedar et al. (2025) and Shirkande et al. (2024) provide encouraging preliminary evidence of efficacy in conditions like LGMD and multiple myeloma(42). However, these are limited by small sample sizes and lack of control groups.

Randomized controlled trials, while methodologically stronger, remain scarce and often suffer from limitations such as inadequate blinding, placebo effects, and heterogeneous outcome measures(43). The RA-1 trial by Chopra et al. (2000) represents one of the better-designed studies, yet even this trial faced methodological challenges that limit definitive conclusions(44).

Quality of Life and Patient-Reported Outcomes

An important dimension of clinical validation involves quality of life and patient-reported outcomes. Poornima and Efferth (2016) highlighted how plant-based Ayurvedic approaches can improve cancer symptom management and quality of life, particularly as adjuncts to conventional therapies(45). Similarly, K et al. (2024) emphasized the role of Ayurvedic herbs in reducing chemotherapy side effects and enhancing overall well-being(46).

These patient-centered outcomes represent a valuable contribution of integrative approaches, addressing dimensions of care that are often overlooked in conventional disease-focused paradigms.

Standardization, Safety, and Quality Control

Current Challenges

Standardization remains a critical challenge in Ayurvedic herbal medicine, particularly for complex polyherbal formulations

and herbo-mineral preparations like Bhasmas(47). Vaidya et al. (2025) highlighted challenges in dose optimization and clinical validation, noting variability in bioactive compound concentrations across different preparations(48). This inconsistency complicates replication of results and comparison across studies, undermining the reliability and clinical applicability of findings.

Safety concerns, while generally favorable compared to conventional treatments, require more systematic investigation. Rajini and Muralidhara (2023) emphasized the need for comprehensive safety assessments and pharmacovigilance systems, particularly regarding potential herb-drug interactions in integrative treatment contexts(49).

Emerging Solutions

Several promising approaches are emerging to address standardization and quality control challenges. Wang and Chen (2024) developed AI-generated GMP (Good Manufacturing Practice) herbal prescriptions for rare diseases, incorporating evidence-based annotations and quality assurance protocols(50). GMP certification represents an important step toward ensuring consistency, safety, and regulatory compliance in herbal medicine production.

Nanotechnology applications, as explored by Lopus (2022), offer potential solutions to bioavailability challenges while enabling more precise dosing and targeted delivery(51). These technological innovations, combined with traditional knowledge, may help bridge the gap between empirical use and evidence-based practice.

Integrative Frameworks and Systems Perspectives

Holistic Disease Models

Ayurvedic conceptual frameworks offer holistic perspectives on rare diseases that complement reductionist biomedical models. Bhandari et al. (2025) correlated classical genetic concepts with modern genomics, demonstrating how systems biology approaches can integrate traditional and contemporary understandings of disease(52). These integrative models acknowledge the multifactorial etiology of rare conditions while providing practical guidance for personalized intervention strategies.

The Anukta Vyadhi framework, which addresses "unclassified" diseases in Ayurvedic terminology, provides a flexible approach to conditions that may not fit neatly into traditional diagnostic categories(53). This framework facilitates the application of Ayurvedic principles to emerging disease entities and rare conditions with complex, multi-system manifestations.

Personalized Medicine Paradigms

The integration of Ayurvedic personalization principles with modern precision medicine represents a particularly promising direction. Madgulwar and Shewalkar (2025) explored Ayurgenomics for personalized health solutions, highlighting how Prakriti-genotype correlations can guide individualized interventions(54). Nilachal et al. (2025) conducted an observational study on the intersection of Ayurgenomics, Deha Prakriti, and yoga therapy in cancer oncology, demonstrating how personalized approaches can optimize treatment responses(55).

These personalized paradigms acknowledge the substantial heterogeneity in disease presentation, progression, and treatment response among individuals with rare conditions, offering more nuanced approaches than one-size-fits-all therapeutic strategies.

Future Research Directions

Priority Areas

Several high-priority research directions emerge from the current literature. First, large-scale, multicenter randomized controlled trials with standardized outcome measures are urgently needed to establish efficacy and safety more definitively(56). These trials should incorporate both conventional biomedical endpoints and patient-reported outcomes relevant to quality of life and functional status.

Second, mechanistic studies employing advanced molecular biology, metabolomics, and systems pharmacology approaches are required to elucidate the bioactive compounds, synergistic effects, and molecular targets of complex herbal formulations(57). Such research will enhance rational drug development and optimize therapeutic regimens.

Third, translational validation of Ayurgenomics frameworks through clinical studies integrating genomic and Ayurvedic phenotyping represents a critical frontier. These studies should establish standardized protocols for Prakriti assessment and validate their utility in predicting treatment responses and guiding personalized interventions.

Emerging Technologies

Emerging technologies offer exciting opportunities for advancing Ayurvedic research and clinical application. Artificial intelligence and computational tools show promise for optimizing herbal prescriptions and integrating diverse data sources. Epigenetic investigations may elucidate mechanisms through which Ayurvedic interventions modulate gene expression and disease processes.

Longitudinal studies assessing sustained effects on disease progression and quality of life will provide valuable insights into the disease-modifying potential of Ayurvedic approaches in chronic rare conditions. These studies should employ comprehensive biomarker panels and patient-centered outcome measures to capture multidimensional treatment effects.

CONCLUSION

Indian medicinal plants offer promising therapeutic potential for rare diseases through multifaceted mechanisms including immunomodulation, genetic regulation, and systemic balancing. The integration of Ayurvedic principles with modern

biomedical science, particularly through Ayurgenomics and reverse pharmacology approaches, represents a transformative paradigm for personalized, holistic care of complex conditions.

While preliminary evidence is encouraging, significant challenges remain in standardization, safety validation, and clinical translation. Addressing these challenges through rigorous interdisciplinary research, technological innovation, and collaborative frameworks will be essential for realizing the full potential of Ayurvedic approaches in rare disease management.

The future of rare disease therapeutics likely lies in integrative models that combine the strengths of traditional and contemporary medical systems, offering patients comprehensive, personalized approaches that address both disease pathology and overall well-being. As research in this field advances, Indian medicinal plants may play increasingly important roles in filling therapeutic gaps and improving outcomes for individuals with rare genetic disorders, autoimmune conditions, and cancers..

REFERENCES

1. "Role of Ayurvedic Medicinal Plants in Auto-immune Disorders and Their Management." Journal of Ayurveda and Integrated Medical Sciences, 8(3), 108-115, 2023.

2. Wasedar V, Pangam B, Siddhaye A. Ayurveda treatment approach for limb-girdle muscular dystrophy: A case report on significant symptomatic and biochemical improvements. International Journal of Research in Ayurveda and Pharmacy, 16(3), 52-63, 2025.

3. Bhandari S, Acharya AK, Paneru M, Khaljhunia N. Genetic disorders in ayurveda and integrative management approaches. World Journal of Advanced Research and Reviews, 26(3), 2145-2149, 2025.

4. Mukerji M, Asher BP. Ayurgenomics: A new approach in personalized and preventive medicine, 2011.

5. Thakkar AP, Vora A, Buttar HS, Kaur G. Immunomodulating botanicals: An overview of the bioactive phytochemicals for the management of autoimmune disorders, 2024.

6. Wasedar V, Pangam B, Siddhaye A. Ayurveda treatment approach for limb-girdle muscular dystrophy: A case report on significant symptomatic and biochemical improvements. International Journal of Research in Ayurveda and Pharmacy, 16(3), 52-63, 2025.

7. Bhandari S, Acharya AK, Paneru M, Khaljhunia N. Genetic disorders in ayurveda and integrative management approaches. World Journal of Advanced Research and Reviews, 26(3), 2145-2149, 2025.

8. Mugali C, DG S. Ayurvedic management of limb girdle muscular dystrophy - a case report. Journal of Ayurveda and Integrated Medical Sciences, 9(8), 304-308, 2024.

9. Saeed M, Tasleem M, Haque A, Shoaib A, Rizvi SMD. Muscular dystrophies and therapeutic potential of medicinal plants. Deleted Journal, 4(1), 2025.

10. Bez S. Ayurvedic approach to sickle cell disease wsr to sannipatika pandu: An overview, n.d.

11. Bhandari S, Acharya AK, Paneru M, Khaljhunia N. Genetic disorders in ayurveda and integrative management approaches. World Journal of Advanced Research and Reviews, 26(3), 2145-2149, 2025.

12. "Role of Ayurvedic Medicinal Plants in Auto-immune Disorders and Their Management." Journal of Ayurveda and Integrated Medical Sciences, 8(3), 108-115, 2023.

13. Thakkar AP, Vora A, Buttar HS, Kaur G. Immunomodulating botanicals: An overview of the bioactive phytochemicals for the management of autoimmune disorders, 2024.

14. Sharma R. Shodhana and shamana chikitsa in autoimmune disorders: An ayurvedic perspective. Journal of Ayurveda and Integrated Medical Sciences, 10(6), 314-319, 2025.

15. Bhat H, Sampath P, Pai RJ, Bollor R, Baliga MS, Fayad R. Indian medicinal plants as immunomodulators: Scientific validation of the ethnomedicinal beliefs, 2013.

16. Chopra A, Lavin P, Patwardhan B, Chitre D. Randomized double blind trial of an ayurvedic plant derived formulation for treatment of rheumatoid arthritis. The Journal of Rheumatology, 27(6), 1365-1372, 2000.

17. P SS, Giri P. Ayurvedic management of autoimmune disorders: A systematic review. International Research Journal of Ayurveda & Yoga, 05(07), 165-170, 2022.

18. Sharma R. Shodhana and shamana chikitsa in autoimmune disorders: An ayurvedic perspective. Journal of Ayurveda and Integrated Medical Sciences, 10(6), 314-319, 2025.

19. Singh D, Varshney S, Varshney A. Bridging ancient wisdom and modern oncology: Ayurvedic formulations for arbuda in context of cancer management. Journal of Ayurveda and Integrated Medical Sciences, 10(6), 149-159, 2025.

20. Sundaramourthy D, Venkateshperumal SK, Mishra BK, Muzzammel M. Cancer through the ayurvedic lens: An agadatantra path to healing. Ayush Journal of Integrative Oncology, 1(3 & 4), 40-45, 2024.

21. Singh D, Varshney S, Varshney A. Bridging ancient wisdom and modern oncology: Ayurvedic formulations for arbuda in context of cancer management. Journal of Ayurveda and Integrated Medical Sciences, 10(6), 149-159, 2025.

22. Kuthe S. Integrative oncology: Role of ayurveda in cancer care. International Journal of Indian Medicine, 06(06), 02-09, 2025.

23. Sun C, Nirmalananda S, Jenkins CE, et al. First ayurvedic approach towards green drugs: Anti cervical cancer-cell properties of clerodendrum viscosum root extract. Anti-cancer Agents in Medicinal Chemistry, 13(10), 1469-1476, 2013.

24. Chatterjee S, Ghosh C, Roy P. Application of ayurvedic bhasma for the treatment of cancer. Indian Journal of Ayurveda & Integrative Medicine KLEU, 2024.

25. K JR, Singh OP, Parveen R. The role of herbal medicines and ayurveda in cancer treatment: A comprehensive review. International Journal of Science and Healthcare Research, 9(3), 325-331, 2024.

26. Lopus M. Nano-ayurvedic medicine and its potential in cancer treatment. Journal of Integrative Medicine, 21(2), 117-119, 2022.

27. Madgulwar YD, Shewalkar KJ. The intersection of ayurveda and genomics: Exploring ayurgenomics for personalized health solutions. Journal of Ayurveda and Integrated Medical Sciences, 9(10), 168-177, 2025.

28. Bhandari S, Acharya AK, Paneru M, Khaljhunia N. Genetic disorders in ayurveda and integrative management approaches. World Journal of Advanced Research and Reviews, 26(3), 2145-2149, 2025.

29. Mukerji M, Asher BP. Ayurgenomics: A new approach in personalized and preventive medicine, 2011.

30. Juyal RC, Negi S, Wakhode P, et al. Potential of ayurgenomics approach in complex trait research: Leads from a pilot study on rheumatoid arthritis. PLOS ONE, 7(9), 2012.

31. Jangir D, Joshi A, Thrigulla SR, Kumar A, Mukerji M. A systems perspective on rare diseases: Integrating human phenotype ontology with the anukta framework of ayurveda, 2025.

32. Joshi A, Jangir D, Sharma A, et al. Ayurphenoclusters define common molecular roots for rare diseases and uncover ciliary dysfunctions in syndromic conditions, 2024.

33. Jangir D, Joshi A, Thrigulla SR, Kumar A, Mukerji M. A systems perspective on rare diseases: Integrating human phenotype ontology with the anukta framework of ayurveda, 2025.

34. J DV, R D. Ayurveda and epigenetics: Foundations for preventive and precision healthcare, 2025.

35. Keerthi KSSRNNN S, Udainiya N. Epigenetics – an ayurvedic view with respect to prakriti, 2025.

36. Sidhic J, Athira C, Narayanankutty A, George S. Ayurveda-inspired reverse pharmacology in drug discovery, 2024.

37. Balachandran P, Govindarajan R. Ayurvedic drug discovery. Expert Opinion on Drug Discovery, 2(12), 1631-1652, 2007.

38. P SS, Giri P. Ayurvedic management of autoimmune disorders: A systematic review. International Research Journal of Ayurveda & Yoga, 05(07), 165-170, 2022.

39. Shirkande AS, Shirkande A, Changade JV, Tondon V. An ayurvedic evaluation & treatment of multiple myeloma: A case report. Journal of Ayurveda and Integrative Medicine, 15(1), 100865, 2024.

40. Chopra A, Lavin P, Patwardhan B, Chitre D. Randomized double blind trial of an ayurvedic plant derived formulation for treatment of rheumatoid arthritis. The Journal of Rheumatology, 27(6), 1365-1372, 2000.

41. Poornima P, Efferth T. Ayurveda for cancer treatment. Medicinal and Aromatic Plants, 5(5), 1-3, 2016.

42. K JR, Singh OP, Parveen R. The role of herbal medicines and ayurveda in cancer treatment: A comprehensive review. International Journal of Science and Healthcare Research, 9(3), 325-331, 2024.

43. Chatterjee S, Ghosh C, Roy P. Application of ayurvedic bhasma for the treatment of cancer. Indian Journal of Ayurveda & Integrative Medicine KLEU, 2024.

44. Vaidya NG, Lokesh, Shukla R. Dravyaguna in ayurveda: A review of therapeutic potentials and pharmacological evidence. Ayushdhara, 12(2), 204-210, 2025.

45. Rajini P, Muralidhara M. Therapeutic efficacy of ayurvedic polyherbal formulations (PHF): Interactive mechanisms and broad-spectrum activities against neurological disorders, 2023.

46. Wang S, Chen M. Herbal medicine for rare diseases, 2024.

47. Lopus M. Nano-ayurvedic medicine and its potential in cancer treatment. Journal of Integrative Medicine, 21(2), 117-119, 2022.

48. Bhandari S, Acharya AK, Paneru M, Khaljhunia N. Genetic disorders in ayurveda and integrative management approaches. World Journal of Advanced Research and Reviews, 26(3), 2145-2149, 2025.

49. Jangir D, Joshi A, Thrigulla SR, Kumar A, Mukerji M. A systems perspective on rare diseases: Integrating human phenotype ontology with the anukta framework of ayurveda, 2025.

50. Madgulwar YD, Shewalkar KJ. The intersection of ayurveda and genomics: Exploring ayurgenomics for personalized health solutions. Journal of Ayurveda and Integrated Medical Sciences, 9(10), 168-177, 2025.

51. Nilachal P, Bhavanani AB, Gajamanne U, Srivastava V, Karthikeyan K. Observational study on the intersection of ayurgenomics, deha prakriti, and yoga therapy in cancer oncology. Yoga-Mimamsa, 57(1), 9-13, 2025.

52. Wasedar V, Pangam B, Siddhaye A. Ayurveda treatment approach for limb-girdle muscular dystrophy: A case report on significant symptomatic and biochemical improvements. International Journal of Research in Ayurveda and Pharmacy, 16(3), 52-63, 2025.

53. Vaidya NG, Lokesh, Shukla R. Dravyaguna in ayurveda: A review of therapeutic potentials and pharmacological evidence. Ayushdhara, 12(2), 204-210, 2025.

54. Bhandari S, Acharya AK, Paneru M, Khaljhunia N. Genetic disorders in ayurveda and integrative management approaches. World Journal of Advanced Research and Reviews, 26(3), 2145-2149, 2025.

55. Wang S, Chen M. Herbal medicine for rare diseases, 2024.

56. J DV, R D. Ayurveda and epigenetics: Foundations for preventive and precision healthcare, 2025.

57. Wasedar V, Pangam B, Siddhaye A. Ayurveda treatment approach for limb-girdle muscular dystrophy: A case report on significant symptomatic and biochemical improvements. International Journal of Research in Ayurveda and Pharmacy, 16(3), 52-63, 2025..